ID: ALA3299014

Max Phase: Preclinical

Molecular Formula: C22H24N2O6

Molecular Weight: 412.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc2nc(/C=C/C(=O)NC3=C(C(=O)O)CCCC3)ccc2c(OC)c1OC

Standard InChI:  InChI=1S/C22H24N2O6/c1-28-18-12-17-14(20(29-2)21(18)30-3)10-8-13(23-17)9-11-19(25)24-16-7-5-4-6-15(16)22(26)27/h8-12H,4-7H2,1-3H3,(H,24,25)(H,26,27)/b11-9+

Standard InChI Key:  IPCBALBSIKQYFT-PKNBQFBNSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 412.44

Molecular Weight (Monoisotopic): 412.1634

AlogP: 3.30

#Rotatable Bonds: 7

Polar Surface Area: 106.98

Molecular Species: ACID

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.20

CX Basic pKa: 5.12

CX LogP: 0.66

CX LogD: -1.02

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.67

Np Likeness Score: -0.05

References

1. Bobileva O, Bokaldere R, Gailite V, Kaula I, Ikaunieks M, Duburs G, Petrovska R, Mandrika I, Klovins J, Loza E..  (2014)  Synthesis and evaluation of (E)-2-(acrylamido)cyclohex-1-enecarboxylic acid derivatives as HCA1, HCA2, and HCA3 receptor agonists.,  22  (14): [PMID:24864041] [10.1016/j.bmc.2014.05.011]

Source

Source(1):

• Scientific Literature